<SEC-DOCUMENT>0001104659-24-082637.txt : 20240725
<SEC-HEADER>0001104659-24-082637.hdr.sgml : 20240725
<ACCEPTANCE-DATETIME>20240725161510
ACCESSION NUMBER:		0001104659-24-082637
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240722
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240725
DATE AS OF CHANGE:		20240725

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Armata Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0000921114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				911549568
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37544
		FILM NUMBER:		241142241

	BUSINESS ADDRESS:	
		STREET 1:		5005 MCCONNELL AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90066
		BUSINESS PHONE:		310-665-2928

	MAIL ADDRESS:	
		STREET 1:		5005 MCCONNELL AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90066

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AmpliPhi Biosciences Corp
		DATE OF NAME CHANGE:	20130222

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGETED GENETICS CORP /WA/
		DATE OF NAME CHANGE:	19940331
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2420145d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:armp="http://armatapharma.com/20240722">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_armp_armatapharma.com_20240722 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20240722_20240722 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0000921114 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-07-22" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-07-22" id="Fact000004" name="dei:EntityCentralIndexKey">0000921114</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="armp-20240722.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-07-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-22</xbrli:startDate>
        <xbrli:endDate>2024-07-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_909_edei--DocumentType_c20240722__20240722_zmoj5QKPYIVb"><ix:nonNumeric contextRef="AsOf2024-07-22" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 OR 15(d) of
The Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<span id="xdx_90B_edei--DocumentPeriodEndDate_c20240722__20240722_zTmgTDzKCSX5"><ix:nonNumeric contextRef="AsOf2024-07-22" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">July 22, 2024</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="border-bottom: Black 1pt solid; font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b><span id="xdx_909_edei--EntityRegistrantName_c20240722__20240722_zfsA32wFhFed"><ix:nonNumeric contextRef="AsOf2024-07-22" id="Fact000011" name="dei:EntityRegistrantName">ARMATA PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 33%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20240722__20240722_zwtCr79T9jc4"><ix:nonNumeric contextRef="AsOf2024-07-22" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Washington</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 33%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_905_edei--EntityFileNumber_c20240722__20240722_zQ4owni3MEX8"><ix:nonNumeric contextRef="AsOf2024-07-22" id="Fact000013" name="dei:EntityFileNumber">001-37544</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20240722__20240722_zO2FeBra1WN3"><ix:nonNumeric contextRef="AsOf2024-07-22" id="Fact000014" name="dei:EntityTaxIdentificationNumber">91-1549568</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(State or other jurisdiction<br/>
 of incorporation)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(IRS Employer<br/>
 Identification No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border-bottom: Black 1pt solid; text-align: center; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt"><span id="xdx_901_edei--EntityAddressAddressLine1_c20240722__20240722_zX2yHaiZqxDc"><b><ix:nonNumeric contextRef="AsOf2024-07-22" id="Fact000015" name="dei:EntityAddressAddressLine1">5005 McConnell Avenue</ix:nonNumeric></b></span><b>,</b> <b><span id="xdx_903_edei--EntityAddressCityOrTown_c20240722__20240722_zcjPG95FKPsb"><ix:nonNumeric contextRef="AsOf2024-07-22" id="Fact000016" name="dei:EntityAddressCityOrTown">Los Angeles</ix:nonNumeric></span></b><b>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20240722__20240722_zwo3EAWDe995"><ix:nonNumeric contextRef="AsOf2024-07-22" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt"><b></b> <b><span id="xdx_90C_edei--EntityAddressPostalZipCode_c20240722__20240722_z9kcZaGJ7hw"><ix:nonNumeric contextRef="AsOf2024-07-22" id="Fact000018" name="dei:EntityAddressPostalZipCode">90066</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><span style="font-size: 10pt">(Address of principal executive offices)</span></td>
    <td>&#160;</td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90D_edei--CityAreaCode_c20240722__20240722_zSAHrvaQDlLk"><ix:nonNumeric contextRef="AsOf2024-07-22" id="Fact000019" name="dei:CityAreaCode">310</ix:nonNumeric></span>) <span id="xdx_90F_edei--LocalPhoneNumber_c20240722__20240722_zYirEJ3hGCrl"><ix:nonNumeric contextRef="AsOf2024-07-22" id="Fact000020" name="dei:LocalPhoneNumber">655-2928</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_902_edei--WrittenCommunications_c20240722__20240722_zwX2dhHwApXa"><ix:nonNumeric contextRef="AsOf2024-07-22" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Wingdings"><span id="xdx_90D_edei--SolicitingMaterial_c20240722__20240722_zUizQhvFGINk"><ix:nonNumeric contextRef="AsOf2024-07-22" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Wingdings"><span id="xdx_907_edei--PreCommencementTenderOffer_c20240722__20240722_zqWbLcrTOfIf"><ix:nonNumeric contextRef="AsOf2024-07-22" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Wingdings"><span id="xdx_909_edei--PreCommencementIssuerTenderOffer_c20240722__20240722_zCMEtbAvUpFk"><ix:nonNumeric contextRef="AsOf2024-07-22" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Emerging Growth Company&#160;<span style="font-family: Wingdings"><span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20240722__20240722_zDWKc3oJPMUk"><ix:nonNumeric contextRef="AsOf2024-07-22" format="ixt:booleanfalse" id="Fact000025" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 31%; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="vertical-align: bottom; width: 1%; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 30%; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="vertical-align: bottom; width: 1%; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 37%; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20240722__20240722_z67VHQXsDr1b"><ix:nonNumeric contextRef="AsOf2024-07-22" id="Fact000026" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></span></td>
    <td style="padding-right: 1.5pt; padding-left: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20240722__20240722_z53yrJUqBXyk"><ix:nonNumeric contextRef="AsOf2024-07-22" id="Fact000027" name="dei:TradingSymbol">ARMP</ix:nonNumeric></span></span></td>
    <td style="padding-right: 1.5pt; padding-left: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_edei--SecurityExchangeName_c20240722__20240722_zrADVSwUktfk"><ix:nonNumeric contextRef="AsOf2024-07-22" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 5.02</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(e)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July&#160;22,
2024, Mina Pastagia, M.D. (&#8220;<i>Dr.&#160;Pastagia</i>&#8221;) and Armata Pharmaceuticals,&#160;Inc. (the &#8220;<i>Company</i>&#8221;)
entered into an agreement (the &#8220;<i>Amendment</i>&#8221;), which amended certain terms of Dr.&#160;Pastagia&#8217;s Employment Agreement
with the Company, dated September&#160;22, 2020 (the &#8220;<i>Employment Agreement</i>&#8221;). The Amendment updates the Employment
Agreement to reflect the fact that Dr.&#160;Pastagia has been serving as the Company&#8217;s Chief Medical Officer since January&#160;1,
2023 and that her base salary has been $456,800 since her promotion. Additionally, commencing with the 2024 fiscal year, Dr.&#160;Pastagia
will have a target annual bonus opportunity equal to 50% of her annual base salary, with the actual bonus payable in respect of any fiscal
year dependent on actual performance as determined by the Company&#8217;s board of directors or compensation committee. Additionally,
Dr.&#160;Pastagia will be eligible for additional grants pursuant to the Company&#8217;s 2016 Equity Incentive Plan (or any successor
plan) commencing in 2025, with the actual size of any grant to be consistent with her position as the Company&#8217;s Chief Medical Officer
(with the current intent being for any such award to have a grant date fair value equal to $300,000), as determined by the Company&#8217;s
board of directors or compensation committee. In the event that Dr.&#160;Pastagia&#8217;s employment is terminated by the Company without
&#8220;cause&#8221; or if she resigns for &#8220;good reason&#8221; (in each case as defined in the Employment Agreement), then, subject
to her execution of a release and compliance with her post-termination restrictive covenants, she will be entitled to a continuation of
her base salary for 12 months following such termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing
description does not constitute a complete summary of the terms of the Amendment or the Employment Agreement and is qualified in its entirety
by reference to the full text of each of the Amendment and the Employment Agreement, copies of which are filed as Exhibit&#160;10.1 and
Exhibit&#160;10.2, respectively, to this report and incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(d)&#160;Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">
    <p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exhibit<br/>
    No.</b></p></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt; text-align: center"><a href="tm2420145d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><a href="tm2420145d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.&#160;1, dated as of July&#160;22, 2024, to that certain Employment Letter Agreement by and between Mina Pastagia, M.D. and Armata Pharmaceuticals,&#160;Inc., dated as of September&#160;22, 2020.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt; text-align: center"><a href="tm2420145d1_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></a></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><a href="tm2420145d1_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Letter Agreement by and between Mina Pastagia, M.D. and Armata Pharmaceuticals,&#160;Inc., dated as of September&#160;22, 2020.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File (embedded within Inline XBRL document).</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
July&#160;25, 2024</span></td>
    <td colspan="2" style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Armata
    Pharmaceuticals,&#160;Inc.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 50%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 5%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; width: 45%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Richard Rychlik</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Richard Rychlik</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Principal Financial Officer and Corporate Controller</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm2420145d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>AMENDMENT NO. 1</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>TO</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify">This Amendment No. 1 (this &ldquo; <U>Amendment</U>&rdquo;)
to the Employment Agreement (as defined below) is entered into as of July 22, 2024, by and between Armata Pharmaceuticals, Inc. (the &ldquo;<U>Company</U>&rdquo;)
and Mina Pastagia, M.D. (the &ldquo;<U>Employee</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify">WHEREAS, the Company and the Employee
are parties to that certain employment letter agreement, dated September 22, 2020 (the &ldquo;<U>Employment Agreement</U>&rdquo;), which
governs the terms of the Employee&rsquo;s employment with the Company; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify">WHEREAS, the Company and the Employee
now desire to amend the Employment Agreement to memorialize Employee&rsquo;s title and compensation change effective as of January 1,
2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify">NOW, THEREFORE, in consideration of
the covenants and agreements herein contained, the parties hereto hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-size: 10pt">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Capitalized Terms</U>. Capitalized terms that are not defined in this Amendment shall have the meanings ascribed thereto in
the Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: -40.5pt"><FONT STYLE="font-size: 10pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Amendments to Employment Agreement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;
</FONT>The first two sentences of Section 1 of the Employment Agreement are hereby amended and restated in their entirety to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 40.5pt; text-align: justify">&ldquo;Effective as of January
1, 2023, you will serve as the Company&rsquo;s Chief Medical Officer, reporting directly to the Company&rsquo;s Chief Executive Officer,
and will have such duties and responsibilities commensurate with such title.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; The first sentence of Section 2 of
the Employment Agreement is hereby amended and restated in its entirety to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 40.5pt; text-align: justify">&ldquo;Effective as of January
1, 2023, your base salary will be $456,800 per year, less applicable withholdings.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Section 3 of the Employment agreement
is hereby amended and restated in its entirety to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40.5pt; text-align: justify">&ldquo;<B>3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp; Bonus.</B> You
will be eligible to earn an annual performance bonus based on achievement of Company performance objectives to be established by the
Board or its compensation committee and provided to you. Your annual target performance bonus for each fiscal year commencing with
the 2024 fiscal year will be equal to fifty percent (50%), although the amount of any payment will be dependent upon actual
performance as determined by the Board or its compensation committee. Generally, you must be employed by the Company through the
date on which bonuses are paid in order to be eligible to receive a bonus. Your annual performance bonus, if any, shall be paid to
you at the same time as annual bonuses are paid to other senior executives of the Company and, in all events, on or before March 15
of the year following the year to which it relates (or such earlier date as determined by the Board or its compensation committee in
the sole discretion). Your annual target performance bonus percentage is subject to increase, but not decrease, from time to time in
the discretion of the Board or its compensation committee (the &ldquo;<B><I>Compensation Committee</I></B>&rdquo;). For the
avoidance of doubt, the parties hereto acknowledge and agree that the Compensation Committee did not award any annual bonuses to
executive officers of the Company in respect of the 2023 fiscal year and that you have no entitlement to any bonus in respect of
employment during the 2023 fiscal year.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 40.5pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Section 4 of the Employment Agreement is hereby
amended and restated in its entirety to read as following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40.5pt; text-align: justify">&ldquo;<B>4. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;Equity Award</B>. You will be
eligible to receive additional grants pursuant to the Company&rsquo;s 2016 Equity Incentive Plan or any successor thereto (the &ldquo;<B><I>Plan</I></B>&rdquo;)
commencing in 2025. The actual size of your annual grant in respect of any fiscal year shall be consistent with your position as the Company&rsquo;s
Chief Medical Officer, and the terms and conditions of any equity award granted in any fiscal year will be determined in the sole discretion
of the Board and/or the Compensation Committee. The parties hereto acknowledge and agree that the current intent of the Compensation Committee
is that provide you with an equity award each fiscal year (commencing in 2025) with a grant date fair value of approximately $300,000,
but nothing herein shall entitle you to any specific award or any specific terms or conditions in respect of any fiscal year. The parties
also acknowledge and agree that you were granted options and restricted stock units pursuant to the Plan in March 2024 and that you are
not entitled to any additional grant during the 2024 calendar year. Grants shall be made annually (commencing with the Company&rsquo;s
2025 fiscal year) at the same time as grants of equity are made to other senior executives of the Company. Subject to your continued employment
with the Company, any equity awards granted pursuant to this paragraph in respect of any fiscal year shall vest on the same basis as equity
awards granted to other senior executives vest in respect of such fiscal year.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 40.5pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Section 8(a) of the Employment Agreement is
hereby amended and restated in its entirety to read as following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40.5pt; text-align: justify">&ldquo;<B>a.</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp; In the event (i) the Company
terminates your employment without Cause (as defined below and other than due to your death or disability), or (ii) you terminate your
employment for Good Reason (as defined below), and provided in either case of (i) or (ii) such termination or resignation constitutes
a &ldquo;separation from service&rdquo; (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition
thereunder, a &ldquo;<B><I>Separation from Service</I></B>&rdquo;) (such termination or resignation, an &ldquo;<B><I>Involuntary Termination</I></B>&rdquo;),
then, in addition to the Accrued Obligations, subject to your obligations below, you shall be entitled to receive an amount equal to twelve
(12) months of your then current base salary (ignoring any decrease in base salary that forms the basis for Good Reason), less all applicable
withholdings and deductions, paid on the schedule described below (the &ldquo;<B><I>Severance Pay</I></B>&rdquo;).&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; <U>Ratification and Confirmation</U>. Except
as specifically amended by this Amendment, the Employment Agreement is hereby ratified and confirmed in all respects and remains valid
and in full force and effect. Whenever the Employment Agreement is referred to in this Amendment or in any other agreement, document or
instrument, such reference shall be deemed to be to the Employment Agreement, as amended by this Amendment, whether or not specific reference
is made to this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; <U>Entire
Agreement</U>. The Employment Agreement and this Amendment contain the entire understanding and agreement of the parties hereto
regarding the employment of the Employee and supersede all prior negotiations, discussions, correspondence, communications,
understandings and agreements between the parties relating to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Governing Law</U>. This Amendment and the performance hereof shall be construed and governed in accordance with the laws of
the state of California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<U>Controlling Document</U>. In case of conflict between any of the terms and conditions of this Amendment and the Employment Agreement,
the terms and conditions of this Amendment shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Acknowledgment</U>. The Employee acknowledges (i) that the Employee has consulted with or has had the opportunity to consult
with independent counsel of the Employee&rsquo;s own choice concerning this Amendment, and has been advised to do so by the Company, and
(ii) that the Employee has read and understands this Amendment, is fully aware of its legal effect, and has entered into it freely based
on the Employee&rsquo;s own judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<U>Counterparts</U>. This Amendment may be executed in multiple counterparts, each of which shall be deemed an original but all of which
together will constitute one and the same instrument. The execution of this Amendment may be by actual signature or by signature delivered
by facsimile or by e-mail as a portable document format (.pdf) file or image file attachment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">*&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>*&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN WITNESS WHEREOF, the parties have executed this Amendment as of
the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 49%"><FONT STYLE="font-size: 10pt"><B>ARMATA PHARMACUETICALS, INC.</B></FONT></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="width: 47%"><B>EMPLOYEE</B></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 45%">/s/ Deborah Birx</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 47%">/s/ Mina Pastagia</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Name:</TD>
  <TD>Deborah Birx, M.D.</TD>
    <TD>&nbsp;</TD>
  <TD>Mina Pastagia, M.D.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Title:</TD>
  <TD>Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
  <TD></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[<I>Signature Page to Amendment to M. Pastagia Employment
Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>tm2420145d1_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 305pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 305pt; text-align: right"><B>Exhibit 10.2</B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 305pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 50%"><IMG SRC="tm2420145d1_ex10-2img001.jpg" ALT=""></TD><TD STYLE="vertical-align: bottom; text-align: right; width: 50%"><FONT STYLE="font-size: 10pt">4503 Glencoe Avenue<BR>
 Marina
                                                                         del Rey, CA 90292<BR>
 Tel (310) 665-2928 <FONT STYLE="font-family: Symbol">&middot;</FONT> Fax (310) 665-2963<BR>
 www.armatapharma.com</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">September 22, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Ms. Mina Pastagia, MD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Dear Mina:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">We are pleased to confirm our offer of employment with Armata
Pharmaceuticals, Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;), in the position of Vice President, Clinical Development on the terms
set forth in this letter agreement (the &ldquo;<B><I>Agreement</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><B>1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Position. </B>As Vice President, Clinical Development, you will be responsible for managing the clinical research and development
and all clinical trial programs for the Company. You will report directly to the President and Chief Development Officer of the
Company. You agree to devote your full business time and attention to your work for the Company. Except upon the prior written
consent of the Board of Directors of the Company (the &ldquo;<B><I>Board</I></B>&rdquo;), you will not, during your employment with
the Company, (i) accept or maintain any other employment, or (ii) engage, directly or indirectly, in any other business activity
(whether or not pursued for pecuniary advantage) that might interfere with your duties and responsibilities as a Company employee or
create a conflict of interest with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><B>2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;
Salary. </B>Your initial base salary will be $380,000 per year, less applicable withholdings. Your salary will be reviewed from time to
time by the Board or its compensation committee and may be adjusted in the sole discretion of the Board or its compensation committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><B>3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Bonus. </B>You will be eligible to earn an annual performance bonus based on achievement of Company performance objectives to be established
by the Board or its compensation committee and provided to you. Your annual target performance bonus will initially be equal to thirty
five percent (35%), although the amount of any payment will be dependent upon actual performance as determined by the Board or its compensation
committee. Generally, you must be employed by the Company through the date on which bonuses are paid in order to be eligible to receive
a bonus. Your annual target performance bonus, if any, shall be paid to you on or before March 15 of the year following the year to which
it relates. Your annual target performance bonus percentage is subject to modification from time to time in the discretion of the Board
or its compensation committee. You will not be eligible for a cash bonus in calendar 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><B>4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Equity Award. </B>Upon commencement of employment with the Company (expected to be approximately October 15, 2020), you will receive
an Inducement award of 33,000 shares of the Company&rsquo;s common shares (less applicable withholding). These shares will vest
immediately. You will also receive an additional Inducement award of 40,000 shares of the Company&rsquo;s stock (less applicable
withholding), upon commencing employment. This Inducement award will vest six (6) months upon your start date, or on or about
approximately April 15, 2021. Finally, you will receive a third Inducement award of 30,000 shares (less applicable withholding upon
vesting) of the Company&rsquo;s common stock which will cliff vest in their entirety upon the 3<SUP>rd</SUP> anniversary of your
start date (or approximately October 15, 2023). The shares will be issued outside of the Company&rsquo;s 2016 Equity Incentive Plan
(the &ldquo;<B><I>Plan</I></B>&rdquo;). During your employment, depending upon your performance and the Company&rsquo;s success, you
may also be granted options to purchase stock of the Company. The Options shall vest with respect to one-fourth of the total number
of shares on each anniversary of the stock option grant date and, subject to your continued services to the Company. The Options
shall be granted at the fair market value of the stock on the date of grant in accordance with the Plan and shall be subject to the
terms and conditions of the Plan, stock option grant notice and option agreement to be entered into between you and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2420145d1_ex10-2img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; text-align: justify; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="text-align: justify; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 50%"><IMG SRC="tm2420145d1_ex10-2img001.jpg" ALT=""></TD><TD STYLE="vertical-align: bottom; text-align: right; width: 50%"><FONT STYLE="font-size: 10pt">4503 Glencoe Avenue<BR>
 Marina del Rey, CA 90292<BR>
 Tel (310) 665-2928 <FONT STYLE="font-family: Symbol">&middot;</FONT> Fax (310) 665-2963<BR>
 www.armatapharma.com</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><B>5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;
Benefits. </B>You will be eligible to participate in the benefits made generally available by the Company to its senior executives, in
accordance with the benefit plans established by the Company, and as may be amended from time to time in the Company&rsquo;s sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B></FONT><B>At-Will Employment. </B>The Company is an &ldquo;at-will&rdquo; employer. Accordingly, either you or the Company may terminate
the employment relationship at any time, with or without advance notice, and with or without cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;
</B></FONT><B>Termination</B>. Upon any termination of your employment, you will be deemed to have resigned, and you hereby resign, from
all offices and directorships, if any, then held with the Company or any subsidiary. In the event of termination of your employment with
the Company, regardless of the reasons for such termination, the Company shall pay your base salary and accrued but unused vacation up
to and through the date of termination, less applicable payroll and tax withholdings (the &ldquo;<B><I>Accrued Obligations</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-size: 10pt"><B>8.</B></FONT> <B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Severance</B>. You shall be eligible for the severance benefits described in this Section 8.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><B>a.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </B>In the event
(i) the Company terminates your employment without Cause (as defined below and other than due to your death or disability), or (ii) you
terminate your employment for Good Reason (as defined below), and provided in either case of (i) or (ii) such termination or resignation
constitutes a &ldquo;separation from service&rdquo; (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative
definition thereunder, a &ldquo;<B><I>Separation from Service</I></B>&rdquo;) (such termination or resignation, an &ldquo;<B><I>Involuntary
Termination</I></B>&rdquo;), then, in addition to the Accrued Obligations, subject to your obligations below, you shall be entitled to
receive an amount equal to six (6) months of your then current base salary (ignoring any decrease in base salary that forms the basis
for Good Reason), less all applicable withholdings and deductions, paid on the schedule described below (the &ldquo;<B><I>Severance Pay</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><B>b.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </B>The
Severance Pay is conditional upon (i) your continuing to comply with your obligations under your PIIA (as defined in Section 11)
during the period of time in which you are receiving the Severance Pay; (ii) your delivering to the Company an executed separation
agreement and general release of claims in favor of the Company, in a form attached hereto as EXHIBIT A, within the time period set
forth therein, which becomes effective in accordance with its terms, which shall be no later than sixty (60) days following your
Separation from Service (the &ldquo;<B><I>Release</I></B>&rdquo;). The Severance Pay will be paid in equal installments on the
Company&rsquo;s regular payroll schedule over the period outlined above following the date of your Separation from Service; <I>provided,
however,</I> that no payments will be made prior to the sixtieth (60<SUP>th</SUP>) day following your Separation from Service. On
the sixtieth (60<SUP>th</SUP>) day following your Separation from Service, the Company will pay you in a lump sum the amount of the
Severance Pay that you would have received on or prior to such date under the original schedule but for the delay while waiting for
the sixtieth (60<SUP>th</SUP>) day, with the balance of the Severance Pay being paid as originally scheduled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: Red"><IMG SRC="tm2420145d1_ex10-2img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; text-align: justify; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="text-align: justify; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 50%"><IMG SRC="tm2420145d1_ex10-2img001.jpg" ALT=""></TD><TD STYLE="vertical-align: bottom; text-align: right; width: 50%"><FONT STYLE="font-size: 10pt">4503 Glencoe Avenue<BR>
 Marina del Rey, CA 90292<BR>
 Tel (310) 665-2928 <FONT STYLE="font-family: Symbol">&middot;</FONT> Fax (310) 665-2963<BR>
 www.armatapharma.com</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>c.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B></FONT>&ldquo;<B><I>Cause</I></B>&rdquo; for purposes of your Severance Pay means (i) your gross negligence or willful failure substantially
to perform your duties and responsibilities to the Company or deliberate violation of a Company policy; (ii) your commission of any act
of fraud, embezzlement or dishonesty against the Company or any other willful misconduct that has caused or is reasonably expected to
result in material injury to the Company; (iii) your unauthorized use or disclosure of any proprietary information or trade secrets of
the Company or any other party to whom you owe an obligation of nondisclosure as a result of your relationship with the Company; or (iv)
your willful breach of any of your obligations under any written agreement or covenant with the Company, including without limitation
this Agreement and your PIIA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><B>d.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </B>&ldquo;<B><I>Good
Reason</I></B>&rdquo; for purposes of your Severance Pay means the occurrence at any time of any of the following without your prior written
consent: (i) a material reduction in your authority, duties or responsibilities (other than a mere change in title following any merger
or consolidation of the Company with another entity); (ii) a material reduction in your base salary; or (iii) any willful failure or willful
breach by the Company of any of its material obligations under this Agreement. For purposes of this subsection, no act, or failure to
act, on the Company&rsquo;s part shall be deemed &ldquo;willful&rdquo; unless done, or omitted to be done, by the Company not in good
faith and without reasonable belief that the Company&rsquo;s act, or failure to act, was in the best interest of the Company. In order
to terminate your employment under this Agreement for Good Reason, you must (1) provide written notice to the Company within ninety (90)
days of the first occurrence of the events described above, (2) allow the Company at least thirty (30) days from such receipt of such
written notice to cure such event, and (3) if such event is not reasonably cured within such period, resign from all position you then
hold with the Company effective not later than the one-hundred eightieth (180<SUP>th</SUP>) day after the initial occurrence of such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><B>9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Change in Control. </B>If your Involuntary Termination occurs within one (1) month prior to, or twelve (12) months following a Change
in Control (as defined in the Plan), the vesting of all of your outstanding equity awards (including the Options) that are subject to
time-based vesting requirements shall accelerate in full such that all such equity awards shall be deemed fully vested as of the date
of such Involuntary Termination (or Change in Control, if later).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B></FONT><B>Taxes: </B>All amounts paid under this Agreement shall be paid less all applicable state and federal tax withholdings (if
any) and any other withholdings required by any applicable jurisdiction or authorized by you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><B>a. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;Section
409A. </B>The <FONT STYLE="text-decoration: underline double">Severance Pay provided in this Agreement is intended to qualify for an
exemption from application of </FONT>Section 409A of the Internal Revenue Code of 1986, as amended (the &ldquo;<B><I>Code</I></B>&rdquo;)
and the regulations and other guidance thereunder and any state law of similar effect (collectively &ldquo;<B><I>Section 409A</I></B>&rdquo;)
<FONT STYLE="text-decoration: underline double">or to comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A, and any
ambiguities herein shall be interpreted accordingly.</FONT> Each installment of Severance Pay is a separate &ldquo;payment&rdquo; for purposes
of Treasury Regulations Section 1.409A-2(b)(2)(i), and the Severance Pay is intended to satisfy the exemptions from application of Section
409A provided under Treasury Regulations Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if such exemptions are
not available and you are, upon Separation from Service, a &ldquo;specified employee&rdquo; for purposes of Section 409A, then, solely
to the extent necessary to avoid adverse personal tax consequences under Section 409A, the timing of the Severance Pay shall be delayed
until the earlier of (i) six (6) months and one day after your Separation from Service, or (ii) your death. Except to the minimum extent
that payments must be delayed because you are a &ldquo;specified employee&rdquo;, all amounts of Severance Pay will be paid as soon as
practicable in accordance with the schedule provided herein and in accordance with the Company&rsquo;s normal payroll practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2420145d1_ex10-2img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1pt solid; text-align: justify; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="text-align: justify; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 50%"><IMG SRC="tm2420145d1_ex10-2img001.jpg" ALT=""></TD><TD STYLE="vertical-align: bottom; text-align: right; width: 50%"><FONT STYLE="font-size: 10pt">4503 Glencoe Avenue<BR>
 Marina del Rey, CA 90292<BR>
 Tel (310) 665-2928 <FONT STYLE="font-family: Symbol">&middot;</FONT> Fax (310) 665-2963<BR>
 www.armatapharma.com</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><B>b.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Section 280G. </B>If any payment or benefit you will or may receive from the Company
or otherwise (a &ldquo;<B><I>280G Payment</I></B>&rdquo;) would (i) constitute a &ldquo;parachute payment&rdquo; within the meaning
of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the
 &ldquo;<B><I>Excise Tax</I></B>&rdquo;), then any such 280G Payment pursuant to this Agreement or otherwise (a
 &ldquo;<B><I>Payment</I></B>&rdquo;) shall be equal to the Reduced Amount. The &ldquo;<B><I>Reduced Amount</I></B>&rdquo; shall be
either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the
Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined
by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes,
and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the
greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in
a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the
preceding sentence, the reduction shall occur in the manner (the &ldquo;<B><I>Reduction Method</I></B>&rdquo;) that results in the
greatest economic benefit for you. If more than one method of reduction will result in the same economic benefit, the items so
reduced will be reduced pro rata (the &ldquo;<B><I>Pro Rata Reduction Method</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Notwithstanding the
foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes
pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro
Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows:
(A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for you as determined
on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without cause),
shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that
are &ldquo;deferred compensation&rdquo; within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not
deferred compensation within the meaning of Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Unless you and the
Company agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of
the day prior to the effective date of the change of control transaction triggering the Payment shall perform the foregoing calculations.
If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the
change of control transaction, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder.
The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The Company
shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations,
together with detailed supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which your
right to a 280G Payment becomes reasonably likely to occur (if requested at that time by you or the Company) or such other time as requested
by you or the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">If you receive
a Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section 10(b) and the
Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly
return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this this
Section 10(b) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced
Amount was determined pursuant to clause (y) in the first paragraph of this this Section 10(b), you shall have no obligation to
return any portion of the Payment pursuant to the preceding sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2420145d1_ex10-2img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="border-bottom: Black 1pt solid; text-align: justify; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="text-align: justify; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 50%"><IMG SRC="tm2420145d1_ex10-2img001.jpg" ALT=""></TD><TD STYLE="vertical-align: bottom; text-align: right; width: 50%"><FONT STYLE="font-size: 10pt">4503 Glencoe Avenue<BR>
 Marina del Rey, CA 90292<BR>
 Tel (310) 665-2928 <FONT STYLE="font-family: Symbol">&middot;</FONT> Fax (310) 665-2963<BR>
 www.armatapharma.com</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<B>Other</B>. As a condition of employment, you must read, sign and comply with the Company&rsquo;s Proprietary Information and Invention
Assignment Agreement (&ldquo;<B><I>PIIA</I></B>&rdquo;), which (among other provisions) prohibits any unauthorized use or disclosure of
Company proprietary, confidential or trade secret information. As required by law, this offer is subject to satisfactory proof of your
identity and right to work in the United States. Further, if requested by the Company, this offer is contingent upon your successful completion
of a background check to the satisfaction of the Company. If the Company desires that you complete a background check, you will be required
to give your consent for the Company, through an outside firm, to complete a criminal background check and verification of information
provided on your employment application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<B>Entire Agreement</B>. Please let us know of your decision to join the Company by signing a copy of this Agreement and returning it
to us not later than October 15, 2020. This Agreement, together with your PIIA, sets forth our entire agreement and understanding regarding
the terms of your employment with the Company and supersedes any prior representations or agreements, whether written or oral. This Agreement
may not be modified in any way except in a writing signed by the Company&rsquo;s Chief Executive Officer (or another duly authorized officer
of the Company) upon due authorization by the Board or its compensation committee and you. It shall be governed by California law, without
regard to principles of conflicts of laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; text-align: justify">/s/ Todd R. Patrick</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                      <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: justify">Todd R. Patrick</TD><TD STYLE="text-align: justify; width: 50%"></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify">Chief Executive Officer</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify">ACCEPTED AND AGREED:</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-style: normal; font-weight: normal">/s/ Mina Pastagia</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify">Mina Pastagia, MD</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; text-align: justify">Sep 22, 2020</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify">Date</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2420145d1_ex10-2img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="border-bottom: Black 1pt solid; text-align: justify; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="text-align: justify; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 50%"><IMG SRC="tm2420145d1_ex10-2img001.jpg" ALT=""></TD><TD STYLE="vertical-align: bottom; text-align: right; width: 50%"><FONT STYLE="font-size: 10pt">4503 Glencoe Avenue<BR>
 Marina del Rey, CA 90292<BR>
 Tel (310) 665-2928 <FONT STYLE="font-family: Symbol">&middot;</FONT> Fax (310) 665-2963<BR>
 www.armatapharma.com</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>SEPARATION AGREEMENT AND RELEASE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">I enter into this
Separation Agreement and Release (the &ldquo;<B><I>Release</I></B>&rdquo;) pursuant to Section 8 of the Offer Letter Agreement between
Armata Pharmaceuticals, Inc. (the &ldquo;<B><I>Employer</I></B>&rdquo;), and me dated September 22, 2020 (the &ldquo;<B><I>Agreement</I></B>&rdquo;).
I acknowledge that my timely execution and return and my non-revocation of this Release are conditions to the payments and benefits pursuant
to Section 8 of the Agreement. I therefore agree to the following terms:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">1.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Release of Claims</U>. I voluntarily release and forever
discharge the Employer, its affiliated and related entities, its and their respective predecessors, successors and assigns, its and
their respective employee benefit plans and fiduciaries of such plans, and the current and former officers, directors, stockholders,
members, employees, attorneys, accountants and agents of each of the foregoing in their official and personal capacities
(collectively referred to as the &ldquo;<B><I>Releasees</I></B>&rdquo;) generally from all claims, demands, debts, damages and
liabilities of every name and nature, known or unknown (&ldquo;<B><I>Claims</I></B>&rdquo;) that, as of the date when I sign this
Release, I have, ever had, now claim to have or ever claimed to have had against any or all of the Releasees. This release includes,
without limitation, all Claims:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">relating to my employment by the Employer and/or any affiliate of the Employer and
the termination of my employment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">of wrongful discharge;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">of breach of contract;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">of retaliation or discrimination under federal, state or local law (including, without limitation, Claims
of age discrimination or retaliation under the Age Discrimination in Employment Act, Claims of disability discrimination or retaliation
under the Americans with Disabilities Act, Claims of discrimination or retaliation under Title VII of the Civil Rights Act of 1964, Claims
of any form of discrimination or retaliation that is prohibited by the California Fair Employment and Housing Act;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">under any other federal or state statute;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">of defamation or other torts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">of violation of public policy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">for wages, bonuses, incentive compensation, stock, stock options, vacation pay or any other compensation
or benefits (except for such wages, bonuses, incentive compensation, stock, stock options, vacation pay or other compensation or benefits
otherwise due to me under the Agreement); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">for damages or other remedies of any sort, including, without limitation, compensatory
damages, punitive damages, injunctive relief and attorney&rsquo;s fees;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2420145d1_ex10-2img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="border-bottom: Black 1pt solid; text-align: justify; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="text-align: justify; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 50%"><IMG SRC="tm2420145d1_ex10-2img001.jpg" ALT=""></TD><TD STYLE="vertical-align: bottom; text-align: right; width: 50%"><FONT STYLE="font-size: 10pt">4503 Glencoe Avenue<BR>
 Marina del Rey, CA 90292<BR>
 Tel (310) 665-2928 <FONT STYLE="font-family: Symbol">&middot;</FONT> Fax (310) 665-2963<BR>
 www.armatapharma.com</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">I agree that the release set forth in
this section shall be and remain in effect in all respects as a complete general release as to the matters released. This release does
not extend to any obligations incurred under this Release, under any ongoing Company benefit plans or for indemnification under any indemnification
agreement, the Company&rsquo;s Bylaws or applicable law. This release does not release claims that cannot be released as a matter of
law, including, but not limited to, my right to file a charge with or participate in a charge by the Equal Employment Opportunity Commission,
or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related
to employment, against the Company (with the understanding that any such filing or participation does not give me the right to recover
any monetary damages against the Company; my release of claims herein bars me from recovering such monetary relief from the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">I agree that I shall
not seek or accept damages of any nature, other equitable or legal remedies for my own benefit, attorney&rsquo;s fees, or costs from any
of the Releasees with respect to any Claim released by this Release. I represent that I have not assigned to any third party and I have
not filed with any agency or court any Claim released by this Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<U>Ongoing Obligations</U>. I reaffirm my ongoing obligations under the Agreement, including without limitation my obligations under Section
11 with respect to the Proprietary Information and Invention Assignment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<U>No Assignment</U>. I represent that I have not assigned to any other person or entity any Claims against any Releasee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; <U>Right
to Consider and Revoke Release</U>. I acknowledge that I have been given the opportunity to consider this Release for a period of
twenty-one (21) days from the date when it is tendered to me. In the event that I executed this Release within less than twenty-one
(21) days, I acknowledge that such decision was entirely voluntary and that I had the opportunity to consider this Release until the
end of the twenty-one (21) day period. To accept this Release, I shall deliver a signed Release to the Employer&rsquo;s General
Counsel within such twenty-one (21) day period; <I>provided</I> that I acknowledge that the Employer may change the designated
recipient by notice. For a period of seven (7) days from the date when I execute this Release (the &ldquo;<B><I>Revocation
Period</I></B>&rdquo;), I shall retain the right to revoke this Release by written notice that is received by the Employer&rsquo;s
General Counsel or other Employer-designated recipient on or before the last day of the Revocation Period. This Release shall take
effect only if it is executed within the twenty-one (21) day period as set forth above and if it is not revoked pursuant to the
preceding sentence. If those conditions are satisfied, this Release shall become effective and enforceable on the date immediately
following the last day of the Revocation Period (the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&ldquo;<B><I>Effective Date</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp; </FONT><U>California
Civil Code Section 1542</U>. I acknowledge that I have been advised to consult with legal counsel and am familiar with the
provisions of California Civil Code Section 1542, a statute that otherwise prohibits the release of unknown claims, which provides
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2420145d1_ex10-2img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 50%"><IMG SRC="tm2420145d1_ex10-2img001.jpg" ALT=""></TD><TD STYLE="vertical-align: bottom; text-align: right; width: 50%"><FONT STYLE="font-size: 10pt">4503 Glencoe Avenue<BR>
 Marina del Rey, CA 90292<BR>
 Tel (310) 665-2928 <FONT STYLE="font-family: Symbol">&middot;</FONT> Fax (310) 665-2963<BR>
 www.armatapharma.com</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in">A GENERAL RELEASE DOES NOT EXTEND TO
CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN
BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">I, being aware of said code section, agree to expressly waive
any rights I may have thereunder, as well as under any other statute or common law principles of similar effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<U>Other Terms</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; <U>Legal Representation; Review of
Release</U>. I acknowledge that I have been advised to discuss all aspects of this Release with my attorney, that I have carefully read
and fully understand all of the provisions of this Release and that I am voluntarily entering into this Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; <U>Binding Nature of Release</U>. This
Release shall be binding upon me and upon my heirs, administrators, representatives and executors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 1in">(c) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Amendment</U>. This Release may be
amended only upon a written agreement executed by the Employer and me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&nbsp; <U>Severability</U>. In the event that
at any future time it is determined by an arbitrator or court of competent jurisdiction that any covenant, clause, provision or term of
this Release is illegal, invalid or unenforceable, the remaining provisions and terms of this Release shall not be affected thereby and
the illegal, invalid or unenforceable term or provision shall be severed from the remainder of this Release. In the event of such severance,
the remaining covenants shall be binding and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; <U>Governing Law and Interpretation</U>.
This Release shall be deemed to be made and entered into in the State of California, and shall in all respects be interpreted, enforced
and governed under the laws of the State of California, without giving effect to the conflict of laws principles of such State. The language
of all parts of this Release shall in all cases be construed as a whole, according to its fair meaning, and not strictly for or against
either the Employer or me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: Red"><IMG SRC="tm2420145d1_ex10-2img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; color: Red"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 50%"><IMG SRC="tm2420145d1_ex10-2img001.jpg" ALT=""></TD><TD STYLE="vertical-align: bottom; text-align: right; width: 50%"><FONT STYLE="font-size: 10pt">4503 Glencoe Avenue<BR>
 Marina del Rey, CA 90292<BR>
 Tel (310) 665-2928 <FONT STYLE="font-family: Symbol">&middot;</FONT> Fax (310) 665-2963<BR>
 www.armatapharma.com</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; <U>Entire Agreement; Absence of Reliance</U>.
I acknowledge that I am not relying on any promises or representations by the Employer or any of its agents, representatives or attorneys
regarding any subject matter addressed in this Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">So agreed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 85%">
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%"><FONT STYLE="font-style: normal; font-weight: normal">/s/
Mina Pastagia</FONT></TD>
    <TD STYLE="width: 6%">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">Sep 22, 2020</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify">Mina Pastagia, MD</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">Date</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="tm2420145d1_ex10-2img002.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>armp-20240722.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa6CibOdzZR+OYkxtmB6belqryAnj+g9VyfNiuE2Ub0M -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:armp="http://armatapharma.com/20240722" elementFormDefault="qualified" targetNamespace="http://armatapharma.com/20240722">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://armatapharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="armp-20240722_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="armp-20240722_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>armp-20240722_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>armp-20240722_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://armatapharma.com/role/Cover" xlink:href="armp-20240722.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://armatapharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2420145d1_ex10-2img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2420145d1_ex10-2img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ![ -8# 2(  A$! Q$!_\0
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MG@?S[Z%M%'-K,J0I \=Y:EV"Q.Q<D9W.6&57<"<#VXK/\I8[Z[M<(PN$,R[
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M(MW/)]OIFO/_ /A/->_Y[Q?]^A12PM2K'FB%;&4Z,N66YZS14-I/]ILH)_\
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6%S]36K10X)[A&JXNZ2^X****LR/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2420145d1_ex10-2img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2420145d1_ex10-2img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ; BD# 2(  A$! Q$!_\0
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&%!63N?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139629820094768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 22, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 22,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARMATA PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000921114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1549568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5005 McConnell Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Los Angeles<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">655-2928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARMP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M;E ^:AD-<$*Z69E;#=\*B+/C2+UP/>Q8D'(G.O$^['87%AP)^ZU(+T@0G)'
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M<F]P<R]A<' N>&UL4$L! A0#%     @ Y('Y6)<=%N_O    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ Y('Y
M6)E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " #D@?E8\$^E%T $  !O$   &
M@($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ Y('Y
M6)^@&_"Q @  X@P   T              ( !A P  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " #D@?E8EXJ[',     3 @  "P              @ %@#P
M7W)E;',O+G)E;'-02P$"% ,4    " #D@?E8JL0B%C,!   B @  #P
M        @ %)$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ Y('Y6"0>
MFZ*M    ^ $  !H              ( !J1$  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ Y('Y6&60>9(9 0  SP,  !,
M     ( !CA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @
&V!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2420145d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://armatapharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>armp-20240722.xsd</File>
    <File>armp-20240722_lab.xml</File>
    <File>armp-20240722_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2420145d1_8k.htm">tm2420145d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2420145d1_8k.htm": {
   "nsprefix": "armp",
   "nsuri": "http://armatapharma.com/20240722",
   "dts": {
    "schema": {
     "local": [
      "armp-20240722.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "armp-20240722_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "armp-20240722_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2420145d1_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://armatapharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-07-22",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2420145d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-07-22",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2420145d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001104659-24-082637-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-082637-xbrl.zip
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M[P;\U_L%/:5OV@FVXA.?:GH4%F,),M_H1+QZK7A%6@&O0KS;>(1.HFP=P0_
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MW>P!*+SX]-A3J):GGX$AS[VPD#5H8D<N&6NH4/WV?9!$Z!@L(<73I4.Q<SE
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M3IC*77")1CAZ( #B<YQ<VU3 0/I$-A ]_DRJ?2/(-@@KX.1#/YDMK(I:K;S
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MB'JJRXELPL(WZ1!JVC/1V8ZW<S>[]!EII9>5M@&OT>"BY#69B^]BFG947TQ
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M[AMY'P:NK7-EZUSY*9PKF\LK&F37\1UEUWIGUM>B-\J0LVACC4*-0PNPC>9
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M;7 M,C R-# W,C(N>'-D4$L! A0#%     @ Y('Y6)8CKTW]"@  @(8  !4
M             ( !6P,  &%R;7 M,C R-# W,C)?;&%B+GAM;%!+ 0(4 Q0
M   ( .2!^5C@S3^E6P<  -U7   5              "  8L.  !A<FUP+3(P
M,C0P-S(R7W!R92YX;6Q02P$"% ,4    " #D@?E81-T^$G<4  #3<@  $@
M            @ $9%@  =&TR-#(P,30U9#%?.&LN:'1M4$L! A0#%     @
MY('Y6(=_/2.$#P  PTL  !8              ( !P"H  '1M,C0R,#$T-60Q
M7V5X,3 M,2YH=&U02P$"% ,4    " #D@?E8&B#6"9\K  !#"0$ %@
M        @ %X.@  =&TR-#(P,30U9#%?97@Q,"TR+FAT;5!+!08     !@ &
+ (T!  !+9@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>tm2420145d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="armp-20240722.xsd" xlink:type="simple"/>
    <context id="AsOf2024-07-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <startDate>2024-07-22</startDate>
            <endDate>2024-07-22</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-07-22" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-07-22" id="Fact000004">0000921114</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-07-22" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-07-22" id="Fact000010">2024-07-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-07-22" id="Fact000011">ARMATA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-07-22" id="Fact000012">WA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-07-22" id="Fact000013">001-37544</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-07-22" id="Fact000014">91-1549568</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-07-22" id="Fact000015">5005 McConnell Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-07-22" id="Fact000016">Los Angeles</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-07-22" id="Fact000017">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-07-22" id="Fact000018">90066</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-07-22" id="Fact000019">310</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-07-22" id="Fact000020">655-2928</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-07-22" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-07-22" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-07-22" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-07-22" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-07-22" id="Fact000025">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="AsOf2024-07-22" id="Fact000026">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-07-22" id="Fact000027">ARMP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-07-22" id="Fact000028">NYSEAMER</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
